UBS Group AG increased its holdings of Chinese Traditional Chinese Medicine (00570.HK) by 30 million shares at HK$4.31 per share
According to the latest data from the Hong Kong Stock Exchange, on May 8, UBS Group AG increased its holdings of Chinese Traditional Chinese Medicine (00570.HK) by 30 million shares, at a price of HK$43,108 per share, for a total amount of about HK$129 million. After the increase in holdings, the latest number of shares held was approximately 313 million shares, and the latest shareholding ratio was 6.21%.
China Traditional Chinese Medicine (00570.HK) received 30 million additional shares of common stock from UBS, worth approximately HK$129 million
On May 14, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 14, UBS Group AG (UBS Group AG) increased its common stock holdings of $30 million in Chinese Medicine (00570.HK) with an average price of HK$43,108 per share on May 8, worth about HK$129 million. After the increase in holdings, UBS's latest shareholding was 313 million shares, and the good position ratio increased from 5.61% to 6.21%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their public listing
China Traditional Chinese Medicine, Sinopharm Update on Privatization Process Status
China Traditional Chinese Medicine Holdings (HKG:0570) and Sinopharm Common Wealth jointly announced that Sinopharm's representatives have been preparing required documents, notifications, filings and
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
中國中藥:2023年年報
Big Bank Rating | Damo: Raising the target price of Chinese medicines to HK$5.4, attracting valuation
GLONGHUI, April 26 | Damo released a report indicating that after China Traditional Chinese Medicine, the leader in traditional Chinese medicine granules, announced last year's results, the bank reduced its profit estimates for the current year and next two years by about 5% to 6%, reflecting a reduction in sales forecasts for traditional Chinese medicine granules. The forecast was also extended to 2030, and the target price was raised from HK$4.8 to HK$5.4. The valuation was attractive, and the rating “increased”. According to the report, between 2020 and 2025, sales of traditional Chinese medicine granules are expected to grow at an average annual rate of 15% to 20%. With the opening up of the market, hospitals are committed to developing new financial resources outside of Western medicine. The Mainland Government has favorable policies on Chinese medicine granules, which are exempt from being included in pharmaceutical revenue control.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Express News | Guojin Securities: Focus on opportunities such as in vitro diagnostic collection clean-up and proprietary Chinese medicine collection
Express News | Capital Securities: The high dividend rate in the Chinese medicine industry is stable and sustainable
Good sector+performance catalyst, explaining in detail the differences in Tongrentang Technology (01666.HK)'s dual market expectations
Under a series of favorable policies, Tong Ren Tang Technology, as a highly recognizable and even scarce enterprise in the Hong Kong stock market, will benefit.
China Traditional Chinese Medicine Posts 94% Profit Growth in 2023
China Traditional Chinese Medicine Holdings Co (HKG:0570) recorded a 93.6% rise in its net profit to 1.40 billion yuan in 2023, against 720.96 million yuan a year ago, according to a Thursday filing w
China Traditional Chinese Medicine (00570.HK)'s annual net profit of 1,396 billion yuan increased 93.6% year-on-year
Gelonghui, March 21, 丨 China Traditional Chinese Medicine (00570.HK) announced that for the year ended December 31, 2023, the company's turnover was RMB 18.1 billion, up 26.7% from the same period in 2022; net profit was RMB 1,396 billion, up 93.6% from the same period in 2022. No dividend payments were recommended for the year.
TRAD CHI MED: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Chinese Traditional Chinese Medicine (00570.HK): Cheng Xueren resigns as president (i.e. general manager)
Gelonghui, March 21 | Chinese Traditional Chinese Medicine (00570.HK) announced that the board of directors has received written resignation reports from Cheng Xueren and Yang Wenming. Since they have reached the legal retirement age, Cheng Xueren applied to resign as the company's president (i.e. general manager) and be reassigned from the executive director and managing director to non-executive directors; Yang Wenming applied to resign as the company's vice president, and was transferred from the executive director to a non-executive director.
Active privatization and delisting of Hong Kong stocks is increasing. What is a sign?
The limited liquidity of Hong Kong stocks has always been criticized by the market. This has also made it difficult for many listed companies to reflect their fundamentals in market valuations. While stock trading volume is low, they also have to pay a high cost to maintain their listing status. On balance, some companies chose to privatize and delist. Recently, it was reported that Li Ning, the former “Prince of Gymnastics,” is considering privatizing Hong Kong stock listed company Li Ning, and has invited many well-known institutions to participate. At Li Ning's performance meeting on March 20, Li Ning himself responded that any plan that can increase returns for investors will be considered, but there is currently no privatization-related information to be reported to everyone. Judging by the responses, neither
A new wave of privatization of Hong Kong stocks may have arrived. Which targets should we pay attention to?
① CIMC Motor plans to buy back all H shares for HK$1.1 billion and delist. What are the highlights of the transaction? ② A new wave of privatization of Hong Kong stocks is coming, which other companies are preparing offers?
China Traditional Chinese Medicine (00570.HK) plans to hold a board meeting on March 21 to approve annual results
Gelonghui, March 11, 丨 China Traditional Chinese Medicine (00570.HK) announced that the company will hold a board meeting on March 21, 2024 (Thursday) to consider and approve the final results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to consider the payment of a final dividend (if any).
TRAD CHI MED: DATE OF BOARD MEETING
Express News | Debon Securities: Traditional Chinese medicine allocation is cost-effective, focus on small and medium capitalization stocks that have overfallen
Data reveal | What did Beishui buy in February? Raising Chinese capital stocks and buying CNOOC over HK$5.4 billion
The Hong Kong stock market officially came to an end in February. Southbound capital traded a total of HK$446.811 billion, with a net inflow of HK$24.526 billion, an increase of 8% over January, maintaining a net inflow for the 8th consecutive month.
No Data